{"id":3009,"date":"2026-09-09T10:41:00","date_gmt":"2026-09-09T14:41:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3009"},"modified":"2026-09-09T19:39:43","modified_gmt":"2026-09-09T23:39:43","slug":"dabogratinib-establishes-initial-activity-in-fgfr3-altered-nmibc","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3009","title":{"rendered":"Dabogratinib Establishes Initial Activity in FGFR3-Altered NMIBC"},"content":{"rendered":"

Evidence<\/strong> Source-gap catch-up · Published<\/strong> September 9, 2026 · Discovery<\/strong> September 9, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Mixed<\/p>\n

\"Dabogratinib<\/p>\n

Summary<\/h4>\n

Tyra Biosciences reported initial open-label Phase II SURF302 results for oral dabogratinib in adults with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At 60 mg once daily, 11 of 14 efficacy-evaluable participants responded at three months and as best overall response; nine of 14 achieved a best complete response. Activity was strongest in the eight-patient single-marker-lesion subgroup, where all responded and six achieved a best complete response. The safety dataset across 44 participants was predominantly Grade 1 or 2, with no Grade 4 or 5 events. These findings support biological and dose-selection activity, but they do not yet establish durable recurrence prevention or benefit in the planned adjuvant setting.<\/p>\n

What Happened<\/h4>\n

As of the August 31 cutoff, 22 participants had received 60 mg and 22 had received 50 mg. Grade 3 treatment-emergent events occurred in three participants at 60 mg and two at 50 mg. Two Grade 3 events were considered treatment related, both at 50 mg. Tyra reported no clinically significant hyperphosphatemia, nail toxicity or ocular toxicity, no treatment-related discontinuations or dose reductions at 60 mg, and transaminase events in fewer than 10% of participants.<\/p>\n

At 60 mg, the three-month and best overall response rates were both 79% in 14 evaluable participants; the complete-response rate increased from 57% at three months to 64% as best response. At 50 mg, eight of 12 participants responded and four achieved complete response. Among single-marker-lesion participants treated at 60 mg, response was 100% and best complete response was 75%. All five three-month complete responders with a six-month assessment remained in response, and the first participant remained in complete response at 12 months while continuing treatment at month 14.<\/p>\n

Deep Analysis<\/h4>\n

A credible oral precision-therapy signal:<\/strong> FGFR3 is a common oncogenic driver in this disease, and the response concentration at 60 mg with a comparatively limited early FGFR-class toxicity profile supports target engagement and a potentially usable chronic dose. An oral option could reduce the procedure burden associated with intravesical therapy. The small, nonrandomized efficacy set, short follow-up and post hoc emphasis on a favorable eight-patient subgroup temper the interpretation.<\/p>\n

An encouraging marker-lesion study that may not predict adjuvant benefit:<\/strong> The planned registrational use aims to prevent recurrence after visible disease is removed, whereas the current readout measures regression of residual marker lesions. A high marker-lesion response may therefore establish drug activity without forecasting recurrence-free survival. The preliminary exposure-response split—86% response above a specified exposure threshold versus 58% below—could support dose optimization, but small denominators and tumor-burden imbalance make it hypothesis generating.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: same-day company disclosure; open-label Phase II study; 26 efficacy-evaluable and 44 safety-evaluable participants; dose-level response and safety results; one participant with a 12-month complete response. Missing facts: independent review, confidence intervals, lesion-level data, molecular clearance, time to recurrence, recurrence-free survival, longer safety exposure and a controlled comparator. Upgrade evidence would be durable complete responses across the completed cohort and health-authority alignment on a randomized adjuvant design.<\/p>\n

Company and Product Background<\/h4>\n

Tyra Biosciences develops precision medicines around fibroblast-growth-factor-receptor biology. Dabogratinib, formerly TYRA-300, is an investigational oral inhibitor designed to favor FGFR3 over FGFR1, FGFR2 and FGFR4. Selectivity may reduce toxicities associated with broader FGFR blockade, but that differentiation requires confirmation with longer exposure and comparative data.<\/p>\n

Low-grade intermediate-risk non-muscle-invasive bladder cancer frequently recurs and can require repeated cystoscopy, transurethral resection and intravesical treatment. Activating FGFR3 alterations are common in this setting and sustain MAPK and related growth signaling. Dabogratinib is intended to suppress the altered receptor systemically. SURF302 is evaluating dose optimization, response, time to recurrence, duration, recurrence-free survival and progression-free survival. Tyra plans to finish the 60-mg cohort, explore 70 mg in an ablative setting and seek regulatory feedback on a Phase III adjuvant study.<\/p>\n

InSilens Take<\/h4>\n

Dabogratinib has crossed an important but early threshold: oral, selective FGFR3 inhibition produced measurable tumor regression at a dose that appears tolerable over the reported exposure period. The signal is strongest in minimal marker-lesion disease and weaker at 50 mg and in higher-burden disease. That pattern is compatible with an adjuvant strategy, but it is not proof of one. The next value-defining evidence is durable recurrence prevention under a regulator-aligned design, not a larger uncontrolled response denominator.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — the first substantive Phase II evidence supporting an oral FGFR3-selective approach in a common, procedure-intensive form of bladder cancer<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nMixed — response and early tolerability are constructive, while small subgroup sizes, limited duration and a marker-lesion\/adjuvant-endpoint mismatch preserve substantial uncertainty<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — numerical efficacy and safety results, cutoff date, study design and next steps stated in the company disclosure and trial record<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-low — the dataset is early, uncontrolled and not yet informative on recurrence prevention, comparative benefit or chronic safety<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Tyra Biosciences reported initial open-label Phase II SURF302 results for oral dabogratinib in adults with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At 60 mg once daily, 11 of 14 efficacy-evaluable participants responded at three…<\/p>\n","protected":false},"author":1,"featured_media":3012,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[661,659,660,658],"class_list":["post-3009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-bladder-cancer","tag-dabogratinib","tag-fgfr3","tag-tyra-biosciences"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3009"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3009\/revisions"}],"predecessor-version":[{"id":3029,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3009\/revisions\/3029"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3012"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}